SCHEDULE 13G/A: Eventide Asset Management and Affiliates Divest Entire Stake in Aura Biosciences, Reporting Zero Beneficial Ownership

Eventide Asset Management, LLC, along with Finny Kuruvilla, M.D., Ph.D., and Robin C. John, have filed an amended Schedule 13G indicating they no longer beneficially own any shares of Aura Biosciences, Inc. common stock.

Summary

• Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John have filed an Amendment No. 3 to Schedule 13G regarding their holdings in Aura Biosciences, Inc.
• As of March 31, 2025, the reporting persons collectively hold 0 shares of Aura Biosciences, Inc. Common Stock, representing 0% of the class.
• This filing indicates a complete divestment of their previously reported beneficial ownership in the company.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative as a significant institutional investor has fully divested its stake, which could be interpreted by the market as a lack of confidence or a strategic shift away from the company.

Negatives

• The filing indicates that Eventide Asset Management, LLC and its associated individuals, who previously held a reportable stake, have now divested their entire position in Aura Biosciences, Inc., holding 0% of the common stock.

Future Outlook

The document does not provide any forward-looking statements or guidance from Aura Biosciences, Inc. or the reporting persons regarding the company's future performance or strategic direction.

Management Comments

• The reporting persons certify that, to the best of their knowledge and belief, the securities referred to were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing is a standard disclosure of a change in institutional ownership and does not provide broader industry context or trends. It reflects a specific investment decision by Eventide Asset Management regarding its position in a biotechnology company.

Stakeholder Impact

• Shareholders: The divestment by an institutional investor could lead to negative market sentiment and potentially impact the company's stock price, especially if the investor was perceived as a long-term holder or influential.

Key Dates

Keywords

Aura Biosciences, Eventide Asset Management, Schedule 13G, Beneficial Ownership, Divestment, Common Stock, SEC Filing, Institutional Investor, Biotechnology